Sanofi
Mixed Phase 3 results for Sanofi and UCB
July 29, 2015Research and Development LixiLan, Sanofi, UCB, clinical trials, epratuzumab, insulin, insulin glargine, phase III
Two drugs that pharma companies are pinning hopes on for future success have had mixed outcomes in key late-stage clinical …
Sanofi and Regeneron in immuno-oncology push
July 28, 2015Manufacturing and Production, Research and Development Cancer, PD-1 inhibitors, Regeneron, Sanofi, collaboration, immuno-oncology, pd-1
Pharma giants Sanofi and Regeneron are extending the partnership that brought new heart drug Praluent to the market, with a …
FDA and EMA approve heart drug Praluent
July 27, 2015Sales and Marketing EMA, FDA, PCSK9, Regeneron, Sanofi, high cholesterol, praluent
The FDA and the EMA have both approved Sanofi and Regeneron’s new high cholesterol drug Praluent. Regulators on both sides …
New Sanofi boss Brandicourt restructures global business
July 16, 2015Sales and Marketing Oliver Brandicourt, Sanofi
Sanofi is reorganising its pharmaceuticals division to create three new business units from January 2016. Chief executive Oliver Brandicourt has …
Praluent scores positive trial results in Japan
July 9, 2015Research and Development Japan, PCKS9, Regeneron, Sanofi, heart disease, high cholesterol, praluent
Praluent, the new heart drug from Sanofi and Regeneron, has met its primary endpoint in a Phase III study in …
Sanofi’s Toujeo approved in Japan
July 3, 2015Manufacturing and Production, Sales and Marketing Japan, Lantus Lantus XR, Sanofi, diabetes, toujeo, type diabetes
The Ministry of Health, Labor and Welfare in Japan has given Sanofi a marketing authorisation for the diabetes drug the …
Former Sanofi chief executive joins Waypoint
June 23, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Viehbacher, waypoint
The former Sanofi chief executive Christopher Viehbacher is joining Geneva-headquartered business enterprise firm Waypoint Capital as a managing partner.
EU approval for new Sanofi, Merck vaccine
June 18, 2015Sales and Marketing EU, Europe, Merck, Sanofi, Sanofi pasteur msd, brett wells, gardasil 9
Sanofi and Merck are looking forward to a successor to their blockbuster Gardasil now that the European Commission has granted …
Sanofi plays host to German chancellor Angela Merkel
May 29, 2015Manufacturing and Production, Medical Communications, Sales and Marketing France, Germany, Sanofi, angela, brett wells, merkel
German Chancellor Dr Angela Merkel met with Sanofi bosses in Frankfurt to discuss antibiotics and open a new manufacturing facility. …
Sanofi appoints external affairs VP
May 27, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, suresh kumar
Sanofi has said Suresh Kumar is to join the French pharma giant on its executive committee and become executive vice …
Sanofi prostate cancer drug to remain on CDF
May 26, 2015Sales and Marketing CDF, Cancer, NHS, Sanofi, list, prostate
Sanofi has reached an agreement with NHS England to reinstate its prostate cancer drug Jevtana on the Cancer Drugs Fund. …
Sanofi’s rheumatoid arthritis biologic performs
May 22, 2015Sales and Marketing Sanofi, rheumatoid arthritis, sarilumab
French pharma giant Sanofi plans to submit its new rheumatoid arthritis biologic for regulatory approval in the US after it …
Sanofi sues decision aid maker for ‘injurious falsehood’
April 20, 2015Medical Communications, Sales and Marketing Diagnosia, Sanofi, metamizole, tech
A tech start-up says it is being sued by pharma giant Sanofi for presenting facts about a drug’s side effects …
Multiple sclerosis studies underway using existing drugs
April 2, 2015Research and Development, Sales and Marketing MS, Midamor, Prozac, Rilutek, Sanofi, amiloride, covis, fluoxetine, multiple sclerosis, riluzole
Three existing drugs that fight heart disease, depression and motor neurone disease could be used to treat multiple sclerosis (MS) …
Type 1 diabetes market value to double by 2023
March 19, 2015Research and Development, Sales and Marketing GlobalData, NHS, NICE, Sanofi, diabetes, toujeo, type 1
The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts …
Latest content
Five Facts about cardiovascular disease
